Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...

This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

Frontotemporal dementia can be hard to diagnose because while dementia can be part of the illness, it's not a factor in all ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.

More than 240 residents from Lewiston, Auburn and surrounding communities participated in this year’s Lakes and Mountains Walk to End Alzheimer’s on Sept. 14 at Simard Payne Park. Participants raised ...

Researchers in China reported finding β-amyloid (Aβ) deposits along the ocular glymphatic system in patients with Alzheimer's ...

Longview residents were out in front of the Gregg County Courthouse on Saturday to take part in the Walk to End Alzheimer’s ...